SAB Biotherapeutics (SABS) Accumulated Expenses (2020 - 2026)

SAB Biotherapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $5.4 million for Q1 2026.

• Quarterly Accumulated Expenses rose 34.58% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (up 34.58% YoY) and the FY2025 annual result came in at $6.6 million, up 20.3% from the prior year.
• Accumulated Expenses was $5.4 million for Q1 2026 at SAB Biotherapeutics, down from $6.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $11.9 million in Q1 2022 and bottomed at $21542.0 in Q2 2025.
• A 5-year average of $5.3 million and a median of $5.3 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses sank 99.81% — and 2024, when it surged 23139.69%.
• SAB Biotherapeutics' Accumulated Expenses stood at $9.9 million in 2022, then slumped by 65.72% to $3.4 million in 2023, then surged by 60.96% to $5.5 million in 2024, then grew by 20.3% to $6.6 million in 2025, then decreased by 18.19% to $5.4 million in 2026.
• Business Quant data shows SABS's Accumulated Expenses at $5.4 million in Q1 2026, $6.6 million in Q4 2025, and $3.7 million in Q3 2025.